CoChat

Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies

Open access
Stoyanova, Radka, Pollack, Alan, Takhar, Mandeep, Lynne, Charles, Parra, Nestor, Lam, Lucia L.C., Alshalalfa, Mohammed, Buerki, Christine, Castillo, Rosa, Jorda, Merce, Ashab, Hussam Al-deen, Kryvenko, Oleksandr N., Punnen, Sanoj, Parekh, Dipen J., Abramowitz, Matthew C., Gillies, Robert J., Davicioni, Elai, Erho, Nicholas, Ishkanian, Adrian · 2016 · Oncotarget
Cited by 106

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

// Radka Stoyanova 1 , Alan Pollack 1 , Mandeep Takhar 2 , Charles Lynne 3 , Nestor Parra 1 , Lucia L.C. Lam 2 , Mohammed Alshalalfa 2 , Christine Buerki 2 , Rosa Castillo 4 , Merce Jorda 3, 5 , Hussam Al-deen Ashab 2 , Oleksandr N. Kryvenko 3, 5 , Sanoj Punnen 3 , Dipen J. Parekh 3 , Matthew C. Abramowitz 1 , Robert J. Gillies 6 , Elai Davicioni 2 , Nicholas Erho 2 , Adrian Ishkanian 1 1 Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA 2 Reserach and Development, GenomeDx Biosciences, Vancouver, BC, Canada 3 Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA 4 Department of Radiology, University of Miami Miller School of Medicine, Miami, FL, USA 5 Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA 6 Cancer Imaging and Metabolism, Moffitt Cancer Center, Tampa, FL, USA Correspondence to: Radka Stoyanova, email: rstoyanova@med.miami.edu Keywords: prostate cancer, multiparametric MRI, MRI-targeted biopsies, gene expression, radiogenomics Received: February 26, 2016 Accepted: June 30, 2016 Published: July 11, 2016 ABSTRACT Standard clinicopathological variables are inadequate for optimal management of prostate cancer patients. While genomic classifiers have improved patient risk classification, the multifocality and heterogeneity of prostate cancer can confound pre-treatment assessment. The objective was to investigate the association of multiparametric (mp)MRI quantitative features with prostate cancer risk gene expression profiles in mpMRI-guided biopsies tissues. Global gene expression profiles were generated from 17 mpMRI-directed diagnostic prostate biopsies using an Affimetrix platform. Spatially distinct imaging areas (‘habitats’) were identified on MRI/3D-Ultrasound fusion. Radiomic features were extracted from biopsy regions and normal appearing tissues. We correlated 49 radiomic features with three clinically available gene signatures associated with adverse outcome. The signatures contain genes that are over-expressed in aggressive prostate cancers and genes that are under-expressed in aggressive prostate cancers. There were significant correlations between these genes and quantitative imaging features, indicating the presence of prostate cancer prognostic signal in the radiomic features. Strong associations were also found between the radiomic features and significantly expressed genes. Gene ontology analysis identified specific radiomic features associated with immune/inflammatory response, metabolism, cell and biological adhesion. To our knowledge, this is the first study to correlate radiogenomic parameters with prostate cancer in men with MRI-guided biopsy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.10523

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 106

Metadata

Authors
Stoyanova, R., Pollack, A., Takhar, M., Lynne, C., Parra, N., Lam, L. L. C., Alshalalfa, M., Buerki, C., Castillo, R., Jorda, M., Ashab, H. A.-D., Kryvenko, O. N., Punnen, S., Parekh, D. J., Abramowitz, M. C., Gillies, R. J., Davicioni, E., Erho, N., & Ishkanian, A.
Venue
Oncotarget
Published
2016-07-11
Volume
7
Issue
33
Pages
53362-53376
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2467451464
Cited by
106
References
4
FWCI
12.09
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.